Economic impact of HIV/AIDS: a systematic review in five European countries

Health Economics Review

Volumn 4, Issue 1, 2014, Pages

  Trapero Bertran, Marta ^a,b   Oliva Moreno, Juan ^c  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c Departamento de Análisis Económico y Finanzas   (Spain)

Author keywords

Costs; Economic impact; VIH AIDS

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; ECONOMIC ASPECT; HEALTH CARE COST; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LYMPHOCYTE COUNT; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; VIRUS LOAD;

EID: 84971281795     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/s13561-014-0015-5     Document Type: Article

References (39)

1. Fauci AS: The AIDS Epidemic. Considerations for the 21st Century.N Engl J Med 1999, 341:1046–1050.
2. Ojo K, Delaney M: Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs.Int J Health Plann Manage 1997, 12(4):315–326.
3. Beck EJ, Miners AH, Tolley K: The cost of HIV treatment and care. A global review.Pharmacoeconomics 2001, 19(1):13–39.
4. International Labour Organization (ILO): El VIH/SIDA y el mundo del trabajo. Conferencia Internacional del Trabajo, 98a reunión. In Ginebra, Informe IV (1). 2009. (disponible en http://www.ilo.org/public/portugue/region/eurpro/lisbon/pdf/vihsida_spa.pdf).
5. Hellinger FJ: Economic Models of Antirretroviral Therapy: Searching for the Optimal Strategy.Pharmacoeconomics 2006, 24(7):631–42.
6. Oliva J: Labour participation of Spanish people living with HIV between 2001–2004.Health Econ 2010, 19:491–500.
7. Mooser V, Carr A: Antirretroviral therapy-associated hyperlipidaemia in HIV disease.Curr Opin Lipidol 2001, 12(3):313–9.
8. Mallon PW, Cooper DA, Carr A: HIV-associated lipodystrophy.HIV Med 2001, 2(3):166–73.
9. Grupo VIHVIR+: Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por el virus de la inmunodeficiencia humana en España.Med Clin (Barc) 2002, 119(19):721–724.
10. Carr A, Cooper DA: Adverse effects of antirretroviral therapy.Lancet 2000, 356(9239):1423–30.
11. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, Concia E: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.N Engl J Med 1998, 338(5):286–90.
12. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, HIV Outpatient Study Investigators: Mortality in the Highly Active Antirretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study.J Acquir Immune Defic Synd 2006, 43(1):27–34.
13. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of liver disease in patients with HIV infection.Lancet 2011, 377(9772):1198–209.
14. Blas-Garcia A, Esplugues JV, Apostolova N: Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity.Curr Med Chem 2011, [Epub ahead of print].
15. Instituto de Salud Carlos III: Ministerio de Sanidad y Economía, Vigilancia epidemiológica del Sida en España. In Sistema Autonómicos de vigilancia epidemiológica. 2012. Disponible en http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-sida/Informe-VIH-sida-Junio-2012.pdf
16. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN: Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.Arch Intern Med 2006, 166(5):521–8.
17. Achhra AC, Phanuphak P, Amin J: Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries.Curr Opin HIV AIDS 2011, [Epub ahead of print].
18. Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Furrer H, Rickenbach M, Weber R, the Swiss HIV Cohort Study (SHCS): Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study.HIV Med 2011, 12(5):279–288. 10.1111/j.1468-1293.2010.00880.x. Epub 2010 Oct 18.
19. Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C, Ocular Complications of AIDS Research Group: Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors.Clin Infect Dis 2010, 51(8):947–56.
20. European Centre for Disease Prevention and Control (ECDC)/WHO Regional Office for Europe: HIV/AIDS surveillance in Europe 2008. Stockholm: European Centre for Disease Prevention and Control; 2009.
21. Kahn JG, Marseille E: Fighting global AIDS: the value of cost-effectiveness analysis.AIDS 2000, 14(16):2609–10.
22. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piche A, Hankins CA: The Cost-effectiveness of Highly Active Antirretroviral Therapy., Canada 1991–2001.AIDS 2004, 18(18):2411–8.
23. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA: The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States.Med Care 2006, 44(11):990–7.
24. King JT Jr, Justice AC, Roberts MS, Chang CC, Fusco JS, Collaboration in HIV Outcomes Research-US Program Team: Long-term HIV/AIDS Survival Estimation in the Highly Active Antirretroviral Therapy Era.Med Decis Making 2003, 23(1):9–20.
25. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D: Long-term Impact of Highly Active Antirretroviral Therapy on HIV-related Health Care.J Acquir Immune Defic Syndr 2001, 27(1):14–9.
26. Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, Sobolev B, Montaner JS: The Direct Costs of HIV/AIDS Care.Lancet Infect Dis 2006, 6(3):171–7.
27. Scitovsky AA, Rice DP: Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.Public Health Rep 1987, 102(1):5–17.
28. Yelin EH, Greenblatt RM, Hollander H, McMaster JR: The impact of HIV-related illness on employment.Am J Public Health 1991, 81(1):79–84.
29. Leigh JP, Lubeck DP, Farnham P, Fries JF: Potential and actual workdays lost among patients with HIV.J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8(4):392–8.
30. Laursen E, Larsen L: Socio-economic status of AIDS patients.Scand J Soc Med 1995, 23(3):189–92.
31. Dray-Spira R, Lert F, Marimoutou C, Bouhnik AD, Obadia Y: Socio-economic conditions, health status and employment among persons living with HIV/AIDS in France in 2001.AIDS Care 2003, 15(6):739–48.
32. Rabkin JG, McElhiney M, Ferrando SJ, Van Gorp W, Lin SH: Predictors of employment of men with HIV/AIDS: a longitudinal study.Psychosom Med 2004, 66(1):72–8.
33. Goldman DP, Bao Y: Effective HIV treatment and the employment of HIV(+) adults.Health Serv Res 2004, 39(6 Pt 1):1691–712.
34. Bernell SL, Shinogle JA: The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook.Health Policy 2005, 71(2):255–64.
35. Sendi P, Brouwer WB, Bucher HC, Weber R, Battegay M, the Swiss HIV Cohort Study: When time is more than money: The allocation of time between work and leisure in HIV-infected patients.Soc Sci Med 2007, 64(11):2355–61.
36. World Bank: International Monetary Fund (IMF). In World Economic and Financial Surveys, World Economic Outlook Database. Washington D.C. USA: IMF; 2010. Disponible en https://www.imf.org/external/pubs/ft/weo/2010/02/weodata/index.aspx.
37. Mulligan J, Fox-Rushby J, Adam T, Johns B, Mills A: Unit costs of health care inputs in low and middle income regions. In Disease Control Priorities Project 2003, Working Paper No 9;. Available from: http://r4d.dfid.gov.uk/Output/170553/Default.aspx.
38. Liu GG, Guo JJ, Smith SR: Economic costs to business of the HIV/AIDS epidemic.Pharmacoeconomics 2004, 22(18):1181–1194.
39. Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P: The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain.BMC Health Serv Res 2009, 9:55–63.